The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial release generated significant gains, the lapse of its exclusive rights opened the avenue to cheaper alternatives, https://sound-social.com/story11964844/the-copyright-and-big-pharma-a-risky-opportunity